Tuesday, November 5, 2019

Premarket analyst action, Nov. 5

Apellis Pharma (NASDAQ:APLS) initiated with Neutral rating and $33 (8% upside) price target at Credit Suisse.
Aphria (NYSE:APHA) initiated with Overweight rating and $C10.40 (55% upside) price target at Cantor Fitzgerald. Shares up 1% premarket.
Argenx (NASDAQ:ARGX) initiated with Neutral rating and $137 (7% upside) price target at Credit Suisse. Shares down 1% premarket.
Aurora Cannabis (NYSE:ACB) initiated with Neutral rating and C$5.10 (8% upside) price target at Cantor.
BioNTech (NASDAQ:BNTX) initiated with Buy rating and $25 (32% upside) price target at Berenberg. Shares up 4% premarket.
Burcon NutraScience (OTCPK:BUROF) initiated with Buy rating and C$1.50 (55% upside) price target at Eight Capital. Shares up 4% premarket.
Canopy Growth (NYSE:CGC) initiated with Neutral rating and C$27 (2% upside) price target at Cantor. Shares up 1% premarket.
Hexo Corp. (NYSE:HEXO) initiated with Underweight rating and C$2.40 (12% downside risk) price target at Cantor. Shares down 1% premarket.
OrganiGram Holdings (NASDAQ:OGI) initiated with Overweight rating and C$17.10 (295% upside) price target at Cantor. Shares up 3% premarket.
Vir Biotechnology (NASDAQ:VIR) initiated with Buy rating and $37 (135% upside) price target at Goldman Sachs, Outperform at Cowen and Company, Overweight with $25 target at Barclays, Overweight with $25 target at Morgan JPMorgan. Shares up 6% premarket.
UniQure (NASDAQ:QURE) initiated with Outperform rating and $76 (53% upside) price target at Credit Suisse.
Amgen (NASDAQ:AMGN) upgraded to Overweight with a $255 (19% upside) price target at Cantor.
Fulgent Genetics (NASDAQ:FLGT) upgraded to Overweight at Piper Jaffray. Shares up 18% premarket on Q3 beat.
Halozyme (NASDAQ:HALO) upgraded to Equal Weight with a $16 (4% upside) price target at Barclays. Shares up 2% premarket.
Sientra (NASDAQ:SIEN) upgraded to Outperform at William Blair. Shares up 5% premarket.
Stryker (NYSE:SYK) downgraded to Equal Weight with a $207 (1% upside) price target at Barclays.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.